Literature DB >> 27053562

Biodistribution Analyses of a Near-Infrared, Fluorescently Labeled, Bispecific Monoclonal Antibody Using Optical Imaging.

Norman C Peterson1, George G Wilson2, Qihui Huang3, Nazzareno Dimasi4, Kris F Sachsenmeier5.   

Abstract

In recent years, biodistribution analyses of pharmaceutical compounds in preclinical animal models have become an integral part of drug development. Here we report on the use of optical imaging biodistribution analyses in a mouse xenograft model to identify tissues that nonspecifically retained a bispecific antibody under development. Although our bispecific antibody bound both the epidermal growth factor receptor and insulin growth factor 1 receptor are expressed on H358, nonsmall-cell lung carcinoma cells, the fluorescence from labeled bispecific antibody was less intense than expected in xenografted tumors. Imaging analyses of live mice and major organs revealed that the majority of the Alexa Fluor 750 labeled bispecific antibody was sequestered in the liver within 2 h of injection. However, results varied depending on which near-infrared fluorophore was used, and fluorescence from the livers of mice injected with bispecific antibody labeled with Alexa Fluor 680 was less pronounced than those labeled with Alexa Fluor 750. The tissue distribution of control antibodies remained unaffected by label and suggests that the retention of fluorophores in the liver may differ. Given these precautions, these results support the incorporation of optical imaging biodistribution analyses in biotherapeutic development strategies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27053562      PMCID: PMC4825957     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  29 in total

Review 1.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

Review 2.  Bispecific antibodies.

Authors:  Roland E Kontermann; Ulrich Brinkmann
Journal:  Drug Discov Today       Date:  2015-02-26       Impact factor: 7.851

3.  The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.

Authors:  Nazzareno Dimasi; Changshou Gao; Ryan Fleming; Robert M Woods; Xiao-Tao Yao; Lena Shirinian; Peter A Kiener; Herren Wu
Journal:  J Mol Biol       Date:  2009-08-20       Impact factor: 5.469

4.  A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.

Authors:  Teresa Hemmerle; Sarah Wulhfard; Dario Neri
Journal:  Protein Eng Des Sel       Date:  2012-09-12       Impact factor: 1.650

5.  Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats.

Authors:  A G Johansson; T Løvdal; K E Magnusson; T Berg; T Skogh
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

6.  Factors influencing localization of labeled antibodies in tumors.

Authors:  W F Bale; M A Contreras; E D Grady
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

7.  Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Authors:  William F Dall'Acqua; Robert M Woods; E Sally Ward; Susan R Palaszynski; Nita K Patel; Yambasu A Brewah; Herren Wu; Peter A Kiener; Solomon Langermann
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

8.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

9.  Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging.

Authors:  Kristine O Vasquez; Chelsea Casavant; Jeffrey D Peterson
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

10.  Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment.

Authors:  Mark D Girgis; Tove Olafsen; Vania Kenanova; Katelyn E McCabe; Anna M Wu; James S Tomlinson
Journal:  EJNMMI Res       Date:  2011-11-07       Impact factor: 3.138

View more
  6 in total

1.  Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.

Authors:  Michael Dobosz; Ute Haupt; Werner Scheuer
Journal:  MAbs       Date:  2016-09-23       Impact factor: 5.857

2.  Multimodal Nanocarrier Probes Reveal Superior Biodistribution Quantification by Isotopic Analysis over Fluorescence.

Authors:  Hongping Deng; Christian J Konopka; Tzu-Wen L Cross; Kelly S Swanson; Lawrence W Dobrucki; Andrew M Smith
Journal:  ACS Nano       Date:  2020-01-07       Impact factor: 15.881

3.  In vivo biodistribution of topical low molecular weight heparin-taurocholate in a neovascularized mouse cornea.

Authors:  Chan Hee Moon; Ji Yun Lee; Eun Soon Kim; Jin Hyoung Park; Sang-Yeob Kim; Jae Yong Kim; Hungwon Tchah
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

4.  Targeted drug delivery via caveolae-associated protein PV1 improves lung fibrosis.

Authors:  Gabriela M Marchetti; Timothy J Burwell; Norman C Peterson; Jennifer A Cann; Richard N Hanna; Qing Li; Emily L Ongstad; Jonathan T Boyd; Maureen A Kennedy; Weiguang Zhao; Keith W Rickert; Joseph S Grimsby; William F Dall'Acqua; Herren Wu; Ping Tsui; M Jack Borrok; Ruchi Gupta
Journal:  Commun Biol       Date:  2019-03-07

Review 5.  Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.

Authors:  Prashant Dogra; Joseph D Butner; Sara Nizzero; Javier Ruiz Ramírez; Achraf Noureddine; María J Peláez; Dalia Elganainy; Zhen Yang; Anh-Dung Le; Shreya Goel; Hon S Leong; Eugene J Koay; C Jeffrey Brinker; Vittorio Cristini; Zhihui Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-21

6.  Mixing Matrix-corrected Whole-body Pharmacokinetic Modeling Using Longitudinal Micro-computed Tomography and Fluorescence-mediated Tomography.

Authors:  Simin Zuo; Wa'el Al Rawashdeh; Stefanie Rosenhain; Zuzanna Magnuska; Yamoah Grace Gyamfuah; Fabian Kiessling; Felix Gremse
Journal:  Mol Imaging Biol       Date:  2021-07-06       Impact factor: 3.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.